Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Sinoatrial node dysfunction and deafness is a rare genetic disease characterized by congenital severe to profound deafness with no evidence of vestibular dysfunction, associated with sinoatrial node dysfunction with pronounced bradycardia and increased variability of heart rate at rest and episodic syncopes that may be triggered by enhanced physical activity and stress.
Features include always present findings: Hearing loss (hearing impairment), Bradycardia, and Increased heart rate variability; and common findings: Syncope. 5 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 2 | Bradycardia, Increased heart rate variability |
CACNA1D encodes calcium voltage-gated channel subunit alpha1 D (2,161 aa). Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. Highest expression in Pituitary (11.1 TPM) and Lung (8.7 TPM).
Sinoatrial node dysfunction and deafness has been associated with mutations in the CACNA1D gene on chromosome 3.
The CACNA1D protein participates in CACNA1D:CACNA2D2:CACNB2 (Cav1.3 channel) transports Ca2+ into the cytosol of an inner hair cell pathway.
CACNA1D is classified as a druggable target (Clinically Actionable, Druggable Genome, and Ion Channel categories) with score 1.2.
Genetic testing for CACNA1D is available. Testing is considered supportive for diagnosis.
Phenotype severity distribution: 3 always present features, 1 common feature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for sinoatrial node dysfunction and deafness.
3 publications have been identified in PubMed for sinoatrial node dysfunction and deafness. Research spans Basic Science / Preclinical (100%).
Torre E (2026). [PMID: 41342134](https://pubmed.ncbi.nlm.nih.gov/41342134/). *Circulation research*. [Basic Science / Preclinical]
Munyao W (2025). [PMID: 40581120](https://pubmed.ncbi.nlm.nih.gov/40581120/). *The Journal of biological chemistry*. [Basic Science / Preclinical]
Reisqs JB (2025). [PMID: 40564095](https://pubmed.ncbi.nlm.nih.gov/40564095/). *Biomedicines*. [Basic Science / Preclinical]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 1:53 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
1 |
Hearing loss (hearing impairment) |
Age of onset: at birth.